A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

The Division of Cardiovascular Medicine will host the Vanderbilt Cardiovascular Symposium 2016 on May 4, highlighting ongoing vascular and heart-related basic and clinical research.

This month an international HIV prevention trial was launched that is testing the infection-preventing prowess of a monoclonal antibody called VRCO1.

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.

Vanderbilt researchers show that a certain factor negatively impacts the first-line responder cells in the lungs, providing one explanation for why patients with asthma are at greater risk for invasive bacterial disease.

Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

Vanderbilt’s Asthma, Sinus, and Allergy Program has seen an increase in the number of patients being treated for alpha-gal syndrome, commonly known as the red meat allergy linked to tick bites.